Dec 24, 2019
Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-target Drug Discovery Collaboration
Dec 23, 2019
Allergan Receives U.S. FDA Approval for UBRELVY(TM) for the Acute Treatment of Migraine with or without Aura in Adults
Dec 23, 2019
Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer
Dec 20, 2019
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes
Dec 19, 2019
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
Dec 19, 2019
Allergan Foundation Giving Reaches $95 Million Since Inception
Dec 18, 2019
Fat Melting Pharmaceutical Company Raziel Therapeutics Raises $22 Million in Series C Funding Round
Dec 10, 2019
Cutting-Edge Cosmetics Injectables Center Set to Beautify the Valley
Dec 06, 2019
Global Facial Injectables Market Forecast to 2025: Upsurge in Medical Tourism / Increase in the Demand for Combination Treatments / Increase in Healthcare Spending
Dec 06, 2019
Cystic Fibrosis Therapeutics Market to Garner $9.27 Bn, Globally, by 2026 at 9.2% CAGR, Says Allied Market Research
Dec 05, 2019
Global Dermatology Drugs Markets, 2014-2018 & 2019-2022 with Profiles of Johnson & Johnson, Allergan, Galderma, Novartis, GlaxoSmithKline
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Nov 29, 2019
Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019
Nov 28, 2019
Analysis on the World Alzheimer's Therapeutics Market 2019-2025 - Eisai Co, Novartis, Pfizer, Eli Lilly & Company, and Johnson & Johnson are Dominating
Nov 20, 2019
Depression Drugs Market Analysis by Drug Class, Disorder Type, Drug Type, Distribution Channel & Region - Forecast to 2024
Nov 19, 2019
Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives
Nov 18, 2019
The Dry Eye Disease market studied was valued at USD 4,539.22 million in 2018, and is expected to reach USD 6,175.96 million by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019
Nov 12, 2019
Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019
Nov 01, 2019
DermaVita Reports Latest EUIPO Finding on Its Brand JUVEDERM
Oct 28, 2019
FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs